Esoterix
Expected Turnaround Time
3 - 5 days
Turnaround time is defined as the usual number of days from the date of pickup of a specimen for testing to when the result is released to the ordering provider. In some cases, additional time should be allowed for additional confirmatory or additional reflex tests. Testing schedules may vary.
Specimen Requirements
Specimen
Serum
Volume
0.8 mL
Minimum Volume
0.4 mL (Note: This volume does not allow for repeat testing.)
Container
Tiger-top (SST) tube or red-top tube
Collection
Separate within one hour; transfer into a plastic transport tube.
Storage Instructions
Ship refrigerated or frozen on dry ice.
Test Details
Methodology
High-pressure liquid chromatography/tandem mass spectrometry (HPLC/MS-MS)
Reference Interval
Premature Infants Male Range(ng/dL) Female Range(ng/dL) 26-28 weeks Day 4 59-125 5-16 31-35 weeks Day 4 37-198 5-22 Newborns Male Range(ng/dL) Female Range(ng/dL) Newborns 75-400 20-64 Male 1-7 Months: Levels decrease rapidly the first week to 20 - 50, then increase to 60 - 400 between 20 - 60 days. Levels then decline to prepubertal range levels of <2.5 - 10 by 7 months. Female 1-7 Months: Levels decrease during the first month to less than 10 and remain there until puberty. Prepubertal Children Males (1-10 Years): <2.5-10 Females (1-9 Years): <2.5-10 Puberty Tanner Stage Age (years) Male 1 <9.8 2.5-10 2 9.8-14.5 18-150 3 10.7-15.4 100-320 4 11.8-16.2 200-620 5 12.8-17.3 350-970 Tanner Stage Age (years) Female 1 <9.2 <2.5-10 2 9.2-13.7 7-28 3 10.0-14.4 15-35 4 10.7-15.6 13-32 5 11.8-18.6 20-38 Adults Range(ng/dL) Males >18 years 264-916 This LabCorp LC/MS-MS method is currently certified by the CDC Hormone Standardization Program (HoST). Adult male reference interval is based on a population of healthy nonobese males (BMI <30) between 19 and 39 years old.1 Premenopausal females 10-55 Postmenopausal females 7-40
References
1. Travison TG, Vesper HW, Orwoll E, et al. Harmonized reference ranges for circulating testosterone levels in men of four cohort studies in the United States and Europe. J Clin Endocrinal Metab 2017 April; 102(4):1161-1173. doi:10.1210/jc.2016-2935